Sign up for free insights newsletter
Pfizer Inc

Pfizer Inc

PFIZ34SA

Need professional-grade analysis? Visit stockanalysis.com

R$32.80
-4.60%
End of day
Market Cap

$824.00B

P/E Ratio

N/A

Employees

N/A

Dividend Yield

436.00%

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino-2.67-1.010.170.07-0.30-0.47
Calmar-7.01-1.880.290.12-0.10-0.97
Sharpe-2.35-0.740.120.05-0.20-0.38
Omega0.390.871.041.030.990.93
Martin-10.81-4.740.710.24-0.13-1.71
Ulcer6.894.214.385.6943.5215.26

Pfizer Inc (PFIZ34) Price Performance

Pfizer Inc (PFIZ34) trades on SA in BRL. The company is classified in the Healthcare sector under the Drug Manufacturers - General industry. The stock currently trades at BRL32.80, down 4.60% from the previous close.

Over the past year, PFIZ34 has traded between a low of BRL29.92 and a high of BRL36.70. The stock has gained 1.3% over this period. It is currently 10.6% below its 52-week high.

Pfizer Inc has a market capitalization of $824.00B and a dividend yield of 436.00%.

About Pfizer Inc

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Compare Pfizer Inc

Side-by-side comparison against top Healthcare peers.

Company Info

Exchange
SA
Currency
BRL
Country
Brazil

Financial Metrics

Revenue (TTM)
$62.58B
EBITDA
$25.72B
Profit Margin
12.42%
EPS (TTM)
1.78
Book Value
79.43

Technical Indicators

52 Week High
R$37.07
52 Week Low
R$29.76
50 Day MA
R$35.02
200 Day MA
R$33.70
Beta
0.41

Valuation

Trailing P/E
20.21
Forward P/E
N/A
Price/Sales
13.17
Price/Book
0.45
Enterprise Value
$258.94B